MMED.NE - Mind Medicine (MindMed) Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 4.8000 |
| Open | 4.8000 |
| Bid | 4.5000 x N/A |
| Ask | 5.0800 x N/A |
| Day's Range | 4.7900 - 5.1500 |
| 52 Week Range | 2.8800 - 25.6500 |
| Volume | |
| Avg. Volume | 22,367 |
| Market Cap | 186.029M |
| Beta (5Y Monthly) | 2.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4700 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- GlobeNewswire
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
FCM Confident in Ability to Start MM-120 Phase III in 2023 and Obtain FDA Approval In 2026 Dr. Freeman and Other FCM Directors Pledge to Extend Lockup Period For Selling Shares Until June 15, 2026 Time is Running Out to Save MindMed Vote on FCM’s BLUE Proxy to Restore Shareholder Value at MindMed SHERIDAN, Wyo., June 07, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), representing approximately 3.5% of the outstanding common shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed”
Business WireMindMed to Host Investor Day June 2023
NEW YORK, June 07, 2023--MindMed will a host an Analyst Day on Tuesday, June 20th that will focus on the MM-120 program in generalized anxiety disorder (GAD).
Business WireLeading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees
NEW YORK, June 05, 2023--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (the "Company" or "MindMed") today announced that leading proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended shareholders vote for ALL of MindMed’s six highly qualified director nominees at the upcoming Annual Meeting of Shareholders ("Annual Meeting"), scheduled for June 15, 2023.
CNW GroupCedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder.
- GlobeNewswire
FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board
FCM Predicts That the Psychedelic Revolution Will Begin with the FDA’s Likely Groundbreaking Approval of the Drug MDMA, Which is Expected to Occur in the Second Half of 2024 Reiterates that MindMed Must Be Prepared to Leverage this Opportunity FCM’s Plan Will Cut Excessive Spending and Focus Resources on its Flagship Drug LSD (MM-120) FCM Plan Will Have MindMed Start Phase III for MM-120 by End of 2023 and Positioned to Complete FDA Approval By 2026 SHERIDAN, Wyo., June 02, 2023 (GLOBE NEWSWIRE)
Business WireMindMed to Participate at Upcoming Investor Conferences
NEW YORK, June 01, 2023--MindMed announced today that members of the Company’s management team will participate in several June investor conferences.
- GlobeNewswire
FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed
FCM Director Candidates, including Dr. Freeman, and Mr. Jake Freeman, Commit to Not Selling Any of Their MindMed Shares Until June 15, 2025 FCM and its Nominees Stand Behind Their Plan to Drive Value for Shareholders If FCM’s Plan is Enacted, FCM Believes MindMed’s Shares Will be Substantially More Valuable in Two Years Vote on FCM’s BLUE Proxy to Restore MindMed SHERIDAN, Wyo., May 30, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), beneficially owning approximately 3.5% of the outstandi
- GlobeNewswire
FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions
MindMed has Slashed Allocation of Spending on Core Drugs While Executive Compensation has Soared to $51M MindMed Phase IIb Clinical Trial Delayed Greenleaf Health Study, Quoting FDA, Supports FCM’s Plan to Immediately Start an LSD Phase III Trial FCM Publishes Presentation Outlining Overwhelming Case for Change at MindMed and Detailing Plan to Bring LSD Drugs to Millions in Need Urges Shareholders to Vote on FCM’s BLUE Proxy to Restore Shareholder Value SHERIDAN, Wyo., May 25, 2023 (GLOBE NEWSWI
Business WireMindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
NEW YORK, May 25, 2023--MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
Business WireMindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
NEW YORK, May 25, 2023--MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy.
Business WireMindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
NEW YORK, May 24, 2023--MindMed will present preclinical data of MM-402, the Company’s proprietary form of R-MDMA, in a model for autism spectrum disorder.
Business WireMindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
NEW YORK, May 17, 2023--MindMed announced today that the Company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for GAD is over 50% enrolled and dosed.
- GlobeNewswire
FCM Director Nominees Will Put MindMed Drug Development Process Back on Track
FCM Believes MindMed Focused on Pursuing Misguided Clinical Path for MM-120 MindMed Executives, Advisors – Barrow, Karlin, and Liechti – Do Not Have Experience in Bringing Drugs to Market and Are Making Fundamental Errors in Approach MindMed Cash Expected to Run Out in 2024 and Dilution Set to Soar FCM Nominees Have Brought Drugs to Market and Completed Numerous Phase III Trials FCM’s Highly Qualified Nominees Would Start Phase III Study for MM-120 in 2023; Vote on FCM’s BLUE Proxy to Restore Sh
- GlobeNewswire
FCM Releases Letter to Fellow MindMed Shareholders Highlighting Board and Management’s Track Record of Shareholder Value Destruction
MindMed Board has Presided over Botched Regulatory Strategies, Outsized Expenses, Soaring Executive Compensation, and Value Destructive Financings FCM’s Four Highly Qualified Director Nominees to Bring Desperately Needed Accountability, Expertise, and Fresh Shareholder Focused Perspective to the Board Urges MindMed Shareholders to vote FOR All Four of FCM’s Nominees on the BLUE Proxy Card SHERIDAN, Wyo., May 05, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC (“FCM”), which together with its affil
Business WireMindMed Reports First Quarter 2023 Financial Results and Business Highlights
NEW YORK, May 04, 2023--MindMed today reported its financial results for the quarter ended March 31, 2023.
- Business Wire
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
NEW YORK, May 02, 2023--The Board of Directors (the "Board") of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today sent a letter to shareholders highlighting the importance of voting at its upcoming 2023 Annual Meeting of Shareholders (the "Annual Meeting"). By voting for the Board’s nominees, shareholders can support the significant progress t
Business WireMindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
NEW YORK, May 01, 2023--MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update.
Business WireMindMed to Participate in May Investor Conferences
NEW YORK, April 26, 2023--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:
- GlobeNewswire
FCM Nominates Exceptional Director Candidates to Restore MindMed’s Value
Meaningful Change is Needed at MindMed After Years of Poor Performance FCM’s Candidates Have Decades of Relevant Industry Experience and are Laser Focused on Bringing MM-120 to Market FCM to Provide Detailed Operational Plan to Address MindMed’s Operational Challenges SHERIDAN, Wyo., April 21, 2023 (GLOBE NEWSWIRE) -- Today, FCM MM Holdings, LLC ("FCM") announces that it has filed a preliminary proxy statement (the “Proxy Statement”) in connection with its nomination of four exceptional director
Business WireMindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
NEW YORK, April 18, 2023--Presents Highly Qualified Slate of Director Nominees, Including Five Incumbent Board Members and New Independent Candidate David W. Gryska.
Business WireMindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
NEW YORK, April 14, 2023--Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that Prof. Matthias Liechti and Dr. Felix Mueller, MindMed collaborators at University Hospital Basel (UHB) and the University Hospital of Psychiatry, have released positive topline data from a double-blind, investigator-initiated trial evaluating lysergide in the trea
Business WireMindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary
NEW YORK, April 13, 2023--MindMed announces the appointment of Mark R. Sullivan as Chief Legal Officer and Corporate Secretary.
Business WireMindMed Reports Full Year 2022 Financial Results and Business Highlights
NEW YORK, March 09, 2023--Mind Medicine (MindMed) Inc. today reported its financial results for the full-year ended December 31, 2022.
Business WireMindMed to Participate in March Investor Conferences
NEW YORK, February 28, 2023--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences:
Exec EdgeNasdaq Gets a Healthy Dose of Psychedelics With Lucy Scientific
By Exec Edge Editorial Staff Lucy Scientific Discovery Inc. (Nasdaq: LSDI), which focuses on psychotropic drugs and had its initial public offering last week, rang the closing bell at the Nasdaq stock exchange today in New York. The company is focused on becoming the premier research, development, and manufacturing organization for the emerging psychedelics-based medicines […]